Will Oklo Stock Double?
Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…
Buy
57
BCDA Quote, Financials, Valuation and Earnings
Last price:
$2.33
Seasonality move
:
25.78%
Day range:
$2.31 - $2.41
52-week range:
$1.63 - $4.66
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
19.46x
P/B ratio:
13.64x
Volume:
173K
Avg. volume:
168.3K
1-year change:
-23.52%
Market cap:
$12.4M
Revenue:
$58K
EPS (TTM):
-$2.58
Analysts' Opinion
-
Consensus RatingBioCardia has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.00, BioCardia has an estimated upside of 151.05% from its current price of $2.39.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $2.39.
Fair Value
-
According to the consensus of 1 analyst, BioCardia has 151.05% upside to fair value with a price target of $6.00 per share.
BCDA vs. S&P 500
-
Over the past 5 trading days, BioCardia has overperformed the S&P 500 by 13.09% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
BioCardia does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioCardia revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter BioCardia reported revenues of $3K.
Earnings Growth
-
BioCardia has grown year-over-year earnings for 10 quarters straight. In the most recent quarter BioCardia reported earnings per share of -$0.59.
Enterprise value:
11.4M
EV / Invested capital:
--
Price / LTM sales:
19.46x
EV / EBIT:
--
EV / Revenue:
26.70x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.41x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-228.95%
Net Income Margin (TTM):
-1999.77%
Return On Equity:
-938.6%
Return On Invested Capital:
-938.6%
Operating Margin:
-54966.67%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $1.4M | $468K | -- | $55K | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$12.1M | -$10.4M | -$8.5M | -$2.3M | -$2.7M | |
| EBITDA | -$12M | -$10.3M | -$8.4M | -$2.3M | -$2.7M | |
| Diluted EPS | -$9.60 | -$6.98 | -$2.58 | -$1.35 | -$0.59 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $22.7M | $10.7M | $5.3M | $1.3M | $1.2M | |
| Total Assets | $23.3M | $12.8M | $7.1M | $2.7M | $2.2M | |
| Current Liabilities | $4.7M | $3.9M | $4M | $4.1M | $3.2M | |
| Total Liabilities | $4.7M | $5.5M | $5.2M | $5M | $3.7M | |
| Total Equity | $18.6M | $7.4M | $1.9M | -$2.3M | -$1.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$10.2M | -$8.9M | -$8.1M | -$1.5M | -$1.6M | |
| Cash From Investing | -$51K | -$2K | -- | -- | -- | |
| Cash From Financing | $5.2M | $5M | $8.1M | $1.4M | $196K | |
| Free Cash Flow | -$10.3M | -$8.9M | -$8.1M | -$1.5M | -$1.6M | |
BCDA
Sector
Market Cap
$12.4M
$34.5M
Price % of 52-Week High
51.29%
49.05%
Dividend Yield
0%
0%
Shareholder Yield
-75.35%
-1.01%
1-Year Price Total Return
-23.52%
-35.15%
Beta (5-Year)
0.814
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.23
200-day SMA
Buy
Level
$2.33
Bollinger Bands (100)
Buy
Level
2 - 2.6
Chaikin Money Flow
Sell
Level
-196M
20-day SMA
Buy
Level
$2.18
Relative Strength Index (RSI14)
Buy
Level
58.67
ADX Line
Buy
Level
14.16
Williams %R
Sell
Level
-12
50-day SMA
Buy
Level
$2.29
MACD (12, 26)
Buy
Level
0.03
25-day Aroon Oscillator
Sell
Level
-12
On Balance Volume
Neutral
Level
366.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-65.0888)
Sell
CA Score
(Annual)
Level (-14.0279)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (15.395)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Stock Forecast FAQ
In the current month, BCDA has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BCDA average analyst price target in the past 3 months is $6.00.
-
Where Will BioCardia Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioCardia share price will rise to $6.00 per share over the next 12 months.
-
What Do Analysts Say About BioCardia?
Analysts are divided on their view about BioCardia share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioCardia is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is BioCardia's Price Target?
The price target for BioCardia over the next 1-year time period is forecast to be $6.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BCDA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioCardia is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of BCDA?
You can purchase shares of BioCardia via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioCardia shares.
-
What Is The BioCardia Share Price Today?
BioCardia was last trading at $2.33 per share. This represents the most recent stock quote for BioCardia. Yesterday, BioCardia closed at $2.39 per share.
-
How To Buy BioCardia Stock Online?
In order to purchase BioCardia stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why a $5 Stock Is Suddenly a Cash Machine
If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…
Is Roku Stock Undervalued Now?
At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…
Stock Ideas
Buy
69
Is NVDA Stock a Buy?
Market Cap: $4T
P/E Ratio: 56x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 43x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
58
INKT alert for Jul 14
MiNK Therapeutics [INKT] is down 36.03% over the past day.
Buy
51
NEGG alert for Jul 14
Newegg Commerce [NEGG] is down 26.42% over the past day.
Buy
68
ATRO alert for Jul 14
Astronics [ATRO] is down 1.02% over the past day.
